Abstract C025: Identification of an orally bio-available SMARCA2 selective degrader for treatment of SMARCA4 mutant cancers
Sign Up to like & getrecommendations! Published in 2025 at "Molecular Cancer Therapeutics"
DOI: 10.1158/1535-7163.targ-25-c025
Abstract: The BAF (SWI/SNF) chromatin remodelling complex comprises two mutually exclusive ATP-dependent helicase subunits, SMARCA2 (BRM) and SMARCA4 (BRG1), which regulate chromatin architecture by mobilizing and repositioning nucleosomes on DNA. This activity is critical for various… read more here.
Keywords: smarca4; degrader; smarca4 mutant; orally bio ... See more keywords
Abstract 3304: Modulation of enhancer accessibility by SMARCA2 PROTACs synergize with TEAD inhibitors to suppress growth of SMARCA4 mutant lung cancers
Sign Up to like & getrecommendations! Published in 2024 at "Cancer Research"
DOI: 10.1158/1538-7445.am2024-3304
Abstract: The SWI/SNF chromatin remodeling complex is frequently mutated in non-small cell lung cancer with a frequency of 33% in advanced stage disease, making it the most commonly altered complex in lung cancer. Among the various… read more here.
Keywords: cancer; lung; smarca4; smarca4 mutant ... See more keywords
Abstract 7024: Discovery of highly selective, potent and orally bio-available SMARCA2 degraders
Sign Up to like & getrecommendations! Published in 2025 at "Cancer Research"
DOI: 10.1158/1538-7445.am2025-7024
Abstract: The BAF (SWI/SNF) chromatin remodeling complex comprises of two mutually exclusive ATPases, SMARCA2 (BRM) and SMARCA4 (BRG1), that affect the mobilization and positioning of nucleosomes on DNA and thereby regulate important cellular functions including transcription,… read more here.
Keywords: smarca2; selective potent; highly selective; discovery highly ... See more keywords
Clinicopathologic characteristics and immunotherapy outcomes in SMARCA4-mutant (mut) non-small cell lung cancer (NSCLC).
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2020.38.15_suppl.9577
Abstract: 9577Background: The catalytic unit of the SWI/SNF chromatin remodeling complex is encoded by the SMARCA4 gene, which is mutated in ~10% of NSCLCs. We sought to characterize the clinicopathologic ch... read more here.
Keywords: immunotherapy outcomes; smarca4 mutant; mutant mut; clinicopathologic characteristics ... See more keywords
STK11/KEAP1 co-mutations in SMARCA4-mutant advanced non-small cell lung cancer: genetic characteristics and impact on immunotherapy efficacy
Sign Up to like & getrecommendations! Published in 2025 at "Translational Lung Cancer Research"
DOI: 10.21037/tlcr-2025-305
Abstract: Background The impact of STK11/KEAP1 co-mutations on the efficacy of immunotherapy in patients with SMARCA4-mutant advanced non-small cell lung cancer (NSCLC) remains incompletely understood. Our aim was to investigate the effects of STK11/KEAP1 co-mutations on… read more here.
Keywords: mpfs1 months; keap1 mutations; stk11 keap1; smarca4 mutant ... See more keywords